Free Trial
NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

Aprea Therapeutics logo
$1.60 -0.04 (-2.14%)
Closing price 04:00 PM Eastern
Extended Trading
$1.61 +0.01 (+0.88%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aprea Therapeutics Stock (NASDAQ:APRE)

Key Stats

Today's Range
$1.51
$1.67
50-Day Range
$1.47
$1.94
52-Week Range
$1.41
$5.01
Volume
24,024 shs
Average Volume
29,067 shs
Market Capitalization
$8.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Buy

Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Aprea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

APRE MarketRank™: 

Aprea Therapeutics scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Aprea Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aprea Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aprea Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aprea Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aprea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.53% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently increased by 24.92%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aprea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aprea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.53% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently increased by 24.92%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aprea Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Aprea Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    Only 1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aprea Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,120.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    13.63% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 34.19% of the stock of Aprea Therapeutics is held by institutions.

  • Read more about Aprea Therapeutics' insider trading history.
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APRE Stock News Headlines

When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

APRE Stock Analysis - Frequently Asked Questions

Aprea Therapeutics' stock was trading at $3.29 on January 1st, 2025. Since then, APRE stock has decreased by 51.4% and is now trading at $1.60.
View the best growth stocks for 2025 here
.

Aprea Therapeutics, Inc. (NASDAQ:APRE) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.01. The company had revenue of $0.16 million for the quarter. Aprea Therapeutics had a negative trailing twelve-month return on equity of 68.39% and a negative net margin of 1,095.02%.

Aprea Therapeutics's stock reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aprea Therapeutics (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.

Top institutional investors of Aprea Therapeutics include Stonepine Capital Management LLC (1.85%) and Exome Asset Management LLC (0.52%). Insiders that own company stock include Oren Gilad, Marc Duey, Bernd R Seizinger and John P Hamill.
View institutional ownership trends
.

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
5/14/2025
Today
6/23/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APRE
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+839.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.96 million
Net Margins
-1,095.02%
Pretax Margin
-1,095.02%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Price / Cash Flow
N/A
Book Value
$3.55 per share
Price / Book
0.46

Miscellaneous

Free Float
4,777,000
Market Cap
$9.12 million
Optionable
No Data
Beta
1.22
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:APRE) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners